|
Malignant neoplasm of stomach
|
0.320 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Stomach Carcinoma
|
0.320 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.310 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Stomach Neoplasms
|
0.300 |
CausalMutation
|
group |
CGI |
|
|
|
|
Benign neoplasm of stomach
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma in situ of stomach
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Neoplasm of uncertain or unknown behavior of stomach
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Adenocarcinoma of large intestine
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of ovary
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.
|
12902990 |
2003 |
|
ovarian neoplasm
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.
|
12902990 |
2003 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.
|
12902990 |
2003 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.
|
12902990 |
2003 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.
|
12902990 |
2003 |
|
Mammary Ductal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Somatic mutations and altered expression of the candidate tumor suppressors CSNK1 epsilon, DLG1, and EDD/hHYD in mammary ductal carcinoma.
|
14871824 |
2004 |
|
Ductal Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Somatic mutations and altered expression of the candidate tumor suppressors CSNK1 epsilon, DLG1, and EDD/hHYD in mammary ductal carcinoma.
|
14871824 |
2004 |
|
Malignant neoplasm of stomach
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Further analyses to examine the joint effect of MBL2 and IL-1B polymorphisms, previously shown to predispose to stomach cancer, indicated that the combination of at-risk IL-1B genotypes (CT or TT at location -511) and HYD MBL2 haplotype was associated with a 3.5-fold risk (OR = 3.5, 95% CI 1.6-7.6; p = 0.001).
|
16721783 |
2006 |
|
Stomach Carcinoma
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Further analyses to examine the joint effect of MBL2 and IL-1B polymorphisms, previously shown to predispose to stomach cancer, indicated that the combination of at-risk IL-1B genotypes (CT or TT at location -511) and HYD MBL2 haplotype was associated with a 3.5-fold risk (OR = 3.5, 95% CI 1.6-7.6; p = 0.001).
|
16721783 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Putative tumor suppressor EDD interacts with and up-regulates APC.
|
18076571 |
2007 |
|
Colorectal Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Thus, through protein-protein interaction, EDD stabilizes APC and up-regulates APC's function to inhibit beta-catenin, suggesting that EDD could act as a colorectal tumor suppressor.
|
18076571 |
2007 |
|
Adenomatous Polyposis Coli
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, through protein-protein interaction, EDD stabilizes APC and up-regulates APC's function to inhibit beta-catenin, suggesting that EDD could act as a colorectal tumor suppressor.
|
18076571 |
2007 |
|
Atrial Premature Complexes
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Putative tumor suppressor EDD interacts with and up-regulates APC.
|
18076571 |
2007 |
|
ovarian neoplasm
|
0.030 |
Biomarker
|
disease |
LHGDN |
These results identify EDD as a new independent prognostic marker for outcome in serous ovarian cancer, and suggest that pathways involving EDD, including DNA damage responses, may represent new therapeutic targets for chemoresistant ovarian cancer.
|
18349819 |
2008 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Despite differences in the heart failure phenotype, therapy of heart failure in African Americans remains largely the same as in white heart failure cohorts, with the notable exception of the added benefits provided by combination of hydralazine and isosorbide dinitrate (HYD-ISDN), now regarded as highly indicated therapy by both the Heart Failure Society of America and the American College of Cardiology/American Heart Association heart failure guideline committees.
|
19945062 |
2010 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Despite differences in the heart failure phenotype, therapy of heart failure in African Americans remains largely the same as in white heart failure cohorts, with the notable exception of the added benefits provided by combination of hydralazine and isosorbide dinitrate (HYD-ISDN), now regarded as highly indicated therapy by both the Heart Failure Society of America and the American College of Cardiology/American Heart Association heart failure guideline committees.
|
19945062 |
2010 |
|
Presenile dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
To observe the effect of early intervention using extract of Huannao Yicong Decoction (, HYD) on the pathological picture of hippocampus, neurocyte apoptosis, and associated regulatory genes in β-amyloid precursor protein (APP) transgenic mice model of dementia.
|
21660677 |
2011 |